Troponin for surveillance of immune checkpoint inhibitor–associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Troponin for surveillance of immune checkpoint inhibitor–associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis
Clinical Scorecard: Utilizing Troponin for Monitoring Myocarditis Linked to Immune Checkpoint Inhibitors and Assessing Cardiovascular Risks After Treatment: A Comprehensive Review and Meta-Analysis
At a Glance
Category
Detail
Condition
ICI-associated myocarditis
Key Mechanisms
Troponin elevation indicates myocardial injury and is used for surveillance and risk stratification.
Target Population
Adults with cancer receiving immune checkpoint inhibitors.
Care Setting
Cardio-oncology surveillance pathways.
Key Highlights
Troponin elevation is associated with confirmed ICI-associated myocarditis.
High sensitivity but modest positive predictive value for troponin in diagnosing myocarditis.
Elevated troponin levels correlate with increased risk of major adverse cardiovascular events (MACE) and mortality.
Guideline-Based Recommendations
Diagnosis
Troponin should not be interpreted as a standalone diagnostic test.
Management
Prompt multimodality evaluation for suspected ICI-associated myocarditis is recommended.
Monitoring & Follow-up
Serial troponin measurements may be considered during ICI therapy.
Risks
False-positive troponin elevations are common.
Patient & Prescribing Data
Adults (≥18 years) with any cancer type receiving ICI therapy.
Troponin elevation may reflect subclinical myocardial inflammation.
Clinical Best Practices
Baseline cardiovascular assessment before ICI therapy is recommended.
Incorporate clinical evaluation, electrocardiography, and cardiac biomarkers in assessment.
